Despite the unbridled enthusiasm for new obesity drugs, which are expected to drive pharmaceutical sector growth along with delivering weight loss and related health benefits to patients, paying for the long-term use of the chronic treatments in widespread patient populations is going to present an affordability crisis, experts said at the J.P. Morgan Healthcare Conference.
Key Takeaways
- Experts at the J.P. Morgan Healthcare Conference discussed the high cost of paying for new obesity drugs and challenges to market access.
Obesity was a big theme throughout the meeting, held in San Francisco from 8 to 11 January, with nearly every...







